SAN FRANCISCO, CA--(Marketwired - April 28, 2016) - With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targeting orphan diseases -- a type of lymphoma and pediatric Crohn's disease -- are in Phase 3, a treatment for oral mucositis is in Phase 2, and Soligenix's biodefense vaccine and therapeutic platform is backed by significant government funding. In this interview with The Life Sciences Report, Dr. Schaber expands on the status of the company's portfolio.
The Life Sciences Report:
Can you briefly describe your company? What makes Soligenix Inc. (
Christopher Schaber: Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. You may ask whether this is truly unique, since a lot of companies are focused on rare diseases these days. That's true, but our rare or orphan disease focus spans both biotherapeutics and biodefense -- we have been awarded up to $57 million ($57M) in government contract funding to develop our biodefense countermeasures. This has allowed us to develop a robust pipeline of eight programs -- two in Phase 3, and another that has recently completed Phase 2 -- which is quite unique for a company our size. Moreover, the biodefense programs use some of the same active ingredients we pursue in our commercial programs, allowing for…
Continue reading this interview: Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need
About Streetwise Reports -- The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Soligenix Inc. paid Streetwise Reports to produce and distribute this interview. Christopher Schaber had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Dr. Schaber and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Please see Streetwise Reports' terms of use and full legal disclaimer.
Contact Information:
Jim Patrick